Alpha Genesis Offers Full-Service Preclinical Support for Federal Funding Applicants

YEMASSEE, S.C., November 12, 2026 /CourierPR/ -- Alpha Genesis, Inc., a full-service preclinical contract research organization, has announced a new initiative aimed at helping biotechnology companies, academic investigators, and research institutions plan and budget preclinical studies for U.S. federal funding proposals. The company offers full-service preclinical research in rodent and nonhuman primate models, from study design and execution through data collection and reporting. Alpha Genesis supports proof-of-concept, pharmacokinetic, and biodistribution studies, as well as follow-on efficacy, dose-ranging, and toxicology studies, including GLP toxicology where appropriate.

The company will provide a letter of interest describing the proposed work and the company's anticipated responsibilities if the project is funded, as well as facility and animal welfare documentation for applicants proposing Alpha Genesis as a U.S. research performance site. Alpha Genesis maintains a Domestic Animal Welfare Assurance with the NIH Office of Laboratory Animal Welfare (D16-00387), holds AAALAC International accreditation, and conducts animal research under IACUC oversight.

Alpha Genesis will also offer reduced pricing for qualifying studies in its written estimates. The company has launched AGI Ventures in September 2026 with an initial $50 million commitment in research services and strategic investments for selected biotechnology companies. A company preparing a federally funded proof-of-concept study can engage Alpha Genesis on a fee-for-service basis and separately ask AGI Ventures to evaluate a subsequent study tied to a financing, licensing, or development milestone. Arrangements for selected companies may include research credits, deferred study fees, or strategic investment, with terms negotiated separately.

Applicants should include the funding opportunity, submission deadline, and a brief, nonconfidential description of the question the study needs to answer. They can request a written estimate, a letter of interest, or both.

Upcoming 2027 submission dates include January 5 and April 5 for the NIH parent SBIR and STTR opportunities, February 5 for new applications under the NIH parent R01 announcement, February 16 for new applications under the NIH parent R21 announcement, and March 4 and July 7 for NSF's SBIR/STTR solicitation NSF 26-510. ARPA-H Mission Office Innovative Solution Openings accept submissions on a rolling basis. Department of Defense research deadlines vary by solicitation.

Follow-on research through AGI Ventures will be considered on a rolling basis. Applications are reviewed by the company's strategic investment and venture-development division. Alpha Genesis will provide a study quote, a letter of interest, or both, depending on the applicant's needs.

The company's initiative aims to assist biotechnology companies, academic investigators, and research institutions in planning and budgeting preclinical studies for U.S. federal funding proposals. The new initiative includes full-service preclinical research, reduced pricing for qualifying studies, and follow-on research support through AGI Ventures, the company's strategic investment division. Alpha Genesis maintains a Domestic Animal Welfare Assurance with the NIH Office of Laboratory Animal Welfare (D16-00387), holds AAALAC International accreditation, and conducts animal research under IACUC oversight. The company's initiatives are designed to help applicants prepare for upcoming 2027 submission dates, including January 5 and April 5 for the NIH parent SBIR and STTR opportunities, February 5 for new applications under the NIH parent R01 announcement, February 16 for new applications under the NIH parent R21 announcement, and March 4 and July 7 for NSF's SBIR/STTR solicitation NSF 26-510. ARPA-H Mission Office Innovative Solution Openings accept submissions on a rolling basis. Department of Defense research deadlines vary by solicitation. Alpha Genesis will provide a study quote, a letter of interest, or both, depending on the applicant's needs. AGI Ventures will consider follow-on research support and investment applications on a rolling basis. Applications are reviewed by the company's strategic investment and venture-development division.